Clinical Trial Detail

NCT ID NCT03065387
Title Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Everolimus + Neratinib

Neratinib + Palbociclib

Neratinib + Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST